Compare IDEXX Laboratories, Inc. (IDXX) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nike Inc — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Nike Inc trades at $43.31 (market cap $64.49B). The key difference: Nike Inc is the larger of the two by market cap, and Nike Inc pays a 3.77% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NKE | |
|---|---|---|
Market Cap | $44.48B | $64.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $79.24 |
52-Week Low | $520.87 | $40.75 |
Enterprise Value | $45.38B | $66.49B |
Volume | — | 8,887,180 |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Nike (NKE) trades at $43.47, down 0.66% on the day, with a neutral technical signal and mixed sentiment. Recent earnings beats in Q1 2026 (actual $0.72 vs. expected $0.11) highlight operational strength, but revenue declined to $46.31B in 2025. The stock shows a bullish moving average trend, with support near $43 and resistance at $44. A dividend of $0.41 is scheduled for payment on July 1, 2026.
Nike's outlook is cautiously optimistic, supported by strong brand equity and consistent earnings outperformance, though revenue growth remains a challenge. Risks include competitive pressures and macroeconomic headwinds in key markets like China. Analyst consensus leans bullish with a $50.80 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
